Homepage Top Section1

Currently, the company is enrolling a Phase 1 trial analysing ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with MCC. MCC is a rare but aggressive form of

Under the collaboration, AmbioPharm will help Ariceum in manufacturing and supplying cGMP peptide conjugates. The peptide conjugates will be radio-labelled as the radiopharmaceutical end-product and will be used

Under the deal terms, Jazz will get exclusive rights to develop and market the antibody across all indications in the US, Japan, Europe, as well as all other

Under the terms of the deal, the company will be responsible for the supply of 100,000 doses of the vaccine. The company will seek regulatory approval of the

The company was created after the acquisition of Alexion Pharmaceuticals by AstraZeneca last year. The aim of the acquisition is to expedite the expansion of Alexion into genomic

Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are

Amvuttra targets and supresses specific messenger RNA (mRNA) that blocks the wild-type and variant transthyretin (TTR) protein production before it is made. It uses the company’s Enhanced Stabilization

Terlivaz is claimed to be the first and only FDA-approved product that is indicated for improving kidney function in HRS adult patients with quick kidney function reduction. The

Recently, the company announced, EVX-B2, a new discovery project to develop a vaccine candidate for gonorrhea using EDEN, its artificial intelligence (AI) platform. In addition to UMass Chan’s